CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 110 enrolled
Drug / intervention
minoxidil + finasteride +2 moredrug
Likely dose
minoxidil + finasteride 5%from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07076706
NCT07076706Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

Beijing Dayspring Pharmaceutical Technology Co., Ltd·interventional·Posted Jul 22, 2025·Updated Mar 3, 2026

In Brief

A Phase 2 clinical trial evaluating minoxidil + finasteride and Placebo foam for Male Pattern of Hair Loss, Androgenic Alopecia and Androgenetic Alopecia (AGA). Completed, enrolled 110 participants across 8 sites.

Detailed Summary

The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety of CG2001 at the target dose.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMale Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20252026
First PostedJul 22, 2025
Enrollment StartDec 5, 2024
Primary CompletionAug 26, 2025
Study CompletionSep 23, 2025
TodayJul 1, 2026
Enrollment to primary: 9 monthsPosted 11 months ago

Interventions

minoxidil + finasteridedrug

topical foam: 5%minoxidil+0.075%finasteride

minoxidil + finasteridedrug

topical foam: 5%minoxidil+0.1%finasteride

Placebo foamdrug

Topical placebo foam